Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.40 |
| ▸ | ACACB | O00763 | 5/20 | 0.39 |
| ▸ | ACACA | Q13085 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516396 | 0.86 | MAPK1 (0.61) | KDM4EALDH1A1L3MBTL1MAPK1LMNA | |
| SCHEMBL4596521 | 0.84 | KDM4E (0.65) | KDM4EALDH1A1L3MBTL1POLBLMNA | |
| SCHEMBL22529696 | 0.80 | MAPK1 (0.54) | KDM4EALDH1A1L3MBTL1MAPK1LMNA | |
| SCHEMBL30827080 | 0.80 | MAPK1 (0.54) | KDM4EALDH1A1L3MBTL1MAPK1LMNA | |
| SCHEMBL8016820 | 0.77 | KDM4E (0.77) | KDM4EALDH1A1L3MBTL1POLBLMNA | |
| SCHEMBL17869220 | 0.77 | MAPT (0.51) | KDM4EALDH1A1L3MBTL1MAPK1POLB | |
| SCHEMBL32668910 | 0.77 | MAPT (0.51) | KDM4EALDH1A1L3MBTL1MAPK1POLB | |
| SCHEMBL31621360 | 0.76 | ALDH1A1 (0.81) | KDM4EALDH1A1L3MBTL1POLBLMNA | |
| SCHEMBL4597702 | 0.76 | KDM4E (0.62) | KDM4EALDH1A1L3MBTL1POLBLMNA | |
| SCHEMBL30879467 | 0.75 | KDM4E (0.72) | KDM4EALDH1A1L3MBTL1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913741-B2 | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200392137-A1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY | 2020-12-17 | — | — | US | disclosed |
| US-10793569-B2 | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200255429-A1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY | 2020-08-13 | — | — | US | disclosed |
| US-10689382-B2 | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-23 | — | — | US | disclosed |
| US-10508115-B2 | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-12-17 | — | — | US | disclosed |
| US-20190055247-A1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10508115-B2 | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor | TLR7, TLR1, TLR8 | KDM4E 3378/4885ALDH1A1 2375/4885L3MBTL1 2318/4885 |
| US-20200255429-A1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | TLR7, TLR1, TLR8 | KDM4E 3378/4885ALDH1A1 2375/4885L3MBTL1 2318/4885 |
| US-10793569-B2 | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor | TLR7, TLR1, TLR8 | KDM4E 3378/4885ALDH1A1 2375/4885L3MBTL1 2318/4885 |
| US-10913741-B2 | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor | TLR7, TLR1, TLR8 | KDM4E 3265/4885ALDH1A1 2345/4885L3MBTL1 2430/4885 |
| US-20190055247-A1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | TLR7, TLR1, TLR8 | KDM4E 3378/4885ALDH1A1 2375/4885L3MBTL1 2318/4885 |
| US-20200392137-A1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | TLR7, TLR1, TLR8 | KDM4E 3378/4885ALDH1A1 2375/4885L3MBTL1 2318/4885 |
| US-10689382-B2 | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor | TLR7, TLR1, TLR8 | KDM4E 3378/4885ALDH1A1 2375/4885L3MBTL1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.